Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Serina Therapeutics (SER) Income from Non-Controlling Interests (2018 - 2025)

Serina Therapeutics' Income from Non-Controlling Interests history spans 8 years, with the latest figure at -$10000.0 for Q3 2025.

  • For Q3 2025, Income from Non-Controlling Interests rose 62.96% year-over-year to -$10000.0; the TTM value through Sep 2025 reached -$45000.0, up 16.67%, while the annual FY2024 figure was -$66000.0, N/A changed from the prior year.
  • Income from Non-Controlling Interests for Q3 2025 was -$10000.0 at Serina Therapeutics, up from -$14000.0 in the prior quarter.
  • Across five years, Income from Non-Controlling Interests topped out at $12000.0 in Q3 2023 and bottomed at -$58000.0 in Q4 2022.
  • The 5-year median for Income from Non-Controlling Interests is -$9500.0 (2023), against an average of -$12000.0.
  • The largest annual shift saw Income from Non-Controlling Interests crashed 1550.0% in 2022 before it soared 1300.0% in 2023.
  • A 5-year view of Income from Non-Controlling Interests shows it stood at $4000.0 in 2021, then plummeted by 1550.0% to -$58000.0 in 2022, then soared by 120.69% to $12000.0 in 2023, then tumbled by 200.0% to -$12000.0 in 2024, then increased by 16.67% to -$10000.0 in 2025.
  • Per Business Quant, the three most recent readings for SER's Income from Non-Controlling Interests are -$10000.0 (Q3 2025), -$14000.0 (Q2 2025), and -$9000.0 (Q1 2025).